Influence Of XRCC1,XPD,ERCC1,GSRP1,TS Gene Polymorphisms On Outcome Of FOLFOX Chemotherapy For Patients With Gastric Cancer

Abstract Purpose:To investigate whether single nucleotide polymorphisms within genes known or suspected to influence drug activity could predict the efficacy of FOLFOX regimens in patients with advanced gastric cancer. It may have important significance on tailoring medication and improving chemotherapy effect.Methods:A retrospective study of186patients with gastric cancer treated with FOLFOX was performed. Peripheral blood samples were used for genotyping6polymorphisms in XRCC1-399,XPD-751,ERCC1-118, GSTP1-105,TSER and TS-3’UTR.The primary end point was to investigate the association between genotypes and progression-free survival(PFS).Results:The mPFS was9.0months in patients with XRCC1-399G/G genotype, which was2.5months higher than those with other genotypes(P=0.039).Patients with GSTP1-105G/G genotype had a longer mPFS than those with other genotypes(9months vs.7.5months,P=0.018).Patients with TS-3’UTR6bp-/6bp-genotype had a longer mPFS than those with other genotypes(10months vs.7.5months, P=0.041).Patients with more than3favorable alleles had a longer mPFS than those with no more than3favorable alleles (11.5months vs.7months, P=0.008). Only number of the favorable alleles revealed prognostic values for PFS on multivariate analysis(P=0.033,HR=0.411)Conclusion:XRCC1-399G allele,GSTP1-105G allele and TS-3’UTR6bp" allele can improve PFS of patients treated with FOLFOX, respectively. Additionally, the number of the favorable alleles of XRCC1-399,GSTP1-105and TS-3’UTR can be identified as a predictor for FOLFOX regimen.